Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$55.45 USD
+1.13 (2.08%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $55.46 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$55.45 USD
+1.13 (2.08%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $55.46 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Zacks News
Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL
by Arpita Dutt
Key highlights from the pharma sector include J&J's (JNJ) first quarter results and a CRL for Lilly's RA drug.
Is J&J's Pharma Sales Slowdown a Warning for Other Players?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported mixed first-quarter 2017 earnings results on Tuesday.
Roche's (RHHBY) Cancer Drug Gets FDA Nod for Label Expansion
by Zacks Equity Research
Roche Holding AG's (RHHBY) unit, Genentech, announced that its drug Tecentriq (atezolizumab) has received FDA approval on an accelerated basis for initial treatment of people with advanced urothelial carcinoma (mUC).
Bristol-Myers and Nordic Ink Biomarker Collaboration Deal
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) recently announced that it has inked a collaboration agreement with Nordic Bioscience, a Danish company specializing in biomarker technologies.
5 Major Drug Stocks Likely to Beat Q1 Earnings Estimates
by Zacks Equity Research
2017 is expected to be a strong year for drug stocks.
Biogen to License Alzheimer Candidate from Bristol-Myers
by Zacks Equity Research
Biogen Inc. (BIIB) recently announced that it has inked a deal to buy worldwide rights for Bristol-Myers Squibb's (BMY) anti-tau antibody, BMS-986168, for an upfront payment of $300 million.
J&J (JNJ) to Kick Off Pharma Q1 Earnings: Will it Beat?
by Zacks Equity Research
We expect Johnson & Johnson (JNJ), a healthcare bellwether, to beat expectations when it reports first-quarter 2017 results on Apr 18, before the opening bell.
Pharma Stock Roundup: Merck Gets CRL for Label Expansion Effort, Roche Cancer Drug Tops
by Arpita Dutt
Key highlights this week include a complete response letter (CRL) for Merck (MRK) and some positive data from Roche.
Bristol-Myers (BMY) Collaborates with Apexigen for Opdivo
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced a collaboration agreement with clinical-stage biopharmaceutical company Apexigen, Inc.
AbbVie's Elagolix Meets Primary Endpoint in Phase II Study
by Zacks Equity Research
AbbVie Inc. (ABBV) along with Neurocrine Biosciences, Inc. (NBIX) announced positive results from a phase IIb study evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids.
Infinity Pharmaceuticals Focuses on Lead Candidate IPI-549
by Zacks Equity Research
We issued an updated report on Infinity Pharmaceuticals, Inc. (INFI) on Apr 7.
Bristol-Myers' (BMY) sBLA For Opdivo Accepted by the FDA
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) recently announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) for the label expansion of immune-oncology drug Opdivo.
5 Reasons to Invest in Eli Lilly (LLY) Stock Right Now
by Zacks Equity Research
Lily carries a Zacks Rank #2 (Buy).
Bristol-Myers Announces Data on Immuno-oncology Drug Opdivo
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) recently announced encouraging data from various trials on Opdivo.
Bristol-Myers (BMY), Incyte to Advance Clinical Program
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) and Incyte Corporation (INCY) recently announced that the companies will advance their clinical development program.
Athersys (ATHX) Stock Rallies as William Blair Initiates Coverage
by Zacks Equity Research
Shares of Athersys, Inc. (ATHX) surged significantly in the post market trading on Mar 28 after research firm William Blair initiated a coverage on the stock with an outperform rating.
Bristol-Myers (BMY) Opdivo Gets Positive CHMP Opinion
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced that the CHMP has recommended the approval of immunotherapy Opdivo as monotherapy for the treatment of squamous cell cancer of the head and neck (SCCHN) in adults.
Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved
by Arpita Dutt
This week's highlights include rumors regarding Sanofi (SNY) acquiring Flexion, accelerated FDA approval for a Pfizer/Merck KGaA drug and drug pricing.
Infinity Pharma Focuses on Cancer Drug: Competition Looms
by Zacks Equity Research
We issued an updated research report on Infinity Pharmaceuticals, Inc. (INFI) on Mar 20, 2017.
Bristol-Myers Squibb and CytomX Therapeutics Extend Deal
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) and CytomX Therapeutics, Inc. (CTMX), announced an expansion of their 2014 strategic collaboration to discover novel therapies.
6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017
by Zacks Equity Research
Glaxo carries a Zacks Rank #2 (Buy).
Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) posted fourth-quarter 2016 loss of 30 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 34 cents and the year-ago loss of 33 cents.
Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs
by Sweta Killa
President Donald Trump March 7 tweet on increasing competition and lowering drug prices sent fresh shockwaves across the industry.
Repros (RPRX) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Repros Therapeutics Inc. (RPRX) is expected to report fourth-quarter 2016 results this month.
Catalyst Pharma (CPRX): What???s in Store in Q4 Earnings?
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report fourth-quarter 2016 results this month.